ClinicalTrials.govcontrolled
Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligible to Ponatinib.
ClinicalTrials.gov study NCT06514534. IPD Sharing: YES. Countries: 1. Publications: 0.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 16
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4